晚期纤维化或肝硬化患者丙型肝炎治愈后肝细胞癌发病率:一项荟萃分析
该系统综述与荟萃分析纳入44项研究(107,548人年随访),评估晚期纤维化(F3)或肝硬化患者丙型肝炎治愈后肝细胞癌发病率。肝硬化患者发病率为2.1/100人年(95%CI 1.9-2.4),F3纤维化患者为0.5/100人年(95%CI 0.3-0.7)。肝硬化患者中年龄较大和既往失代偿与发病率升高相关,而治愈后随访时间较长与发病率降低相关。
要点
- 肝硬化患者丙型肝炎治愈后肝细胞癌发病率为2.1/100人年(95%CI 1.9-2.4)。
- F3纤维化患者发病率为0.5/100人年(95%CI 0.3-0.7),低于成本效益筛查推荐阈值。
- 肝硬化患者中年龄较大和既往失代偿与肝细胞癌发病率升高相关。
核心结论
- 肝硬化患者丙型肝炎治愈后肝细胞癌发病率随时间下降,年龄较轻和代偿期肝硬化者最低。
- F3纤维化患者发病率显著较低,低于成本效益筛查的推荐阈值。
- 结果应鼓励开发经过验证的预测模型,以更好地识别高危个体,尤其是F3纤维化患者。
研究设计与样本
- 系统综述与荟萃分析,纳入44项研究,共107,548人年随访。
- 评估晚期纤维化(F3)或肝硬化患者丙型肝炎治愈后肝细胞癌发病率。
主要发现
- 肝硬化患者肝细胞癌发病率为2.1/100人年(95%CI 1.9-2.4)。
- F3纤维化患者肝细胞癌发病率为0.5/100人年(95%CI 0.3-0.7)。
- 肝硬化患者中,年龄每增加10岁(平均/中位年龄)的调整率比(aRR)为1.32(95%CI 1.00-1.73)。
- 肝硬化患者中,既往失代偿比例每增加10%的aRR为1.06(95%CI 1.01-1.12)。
- 肝硬化患者中,平均/中位随访时间每增加1年的aRR为0.87(95%CI 0.79-0.96)。
关键数值与推荐
- 肝细胞癌监测推荐用于年发病率超过1.5%的人群。
- 肝硬化患者丙型肝炎治愈后应继续肝细胞癌监测,但是否无限期尚不确定。
- F3纤维化患者的指南推荐不一致。
临床怎么用
- 肝硬化患者丙型肝炎治愈后肝细胞癌发病率随时间下降,年龄较轻和代偿期肝硬化者最低。
- F3纤维化患者肝细胞癌发病率显著较低,低于成本效益筛查的推荐阈值。
- 结果应鼓励开发经过验证的预测模型,以更好地识别高危个体,尤其是F3纤维化患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: HCV cure reduces but does not eliminate the risk of HCC. HCC surveillance is recommended in populations where the incidence exceeds 1.5% per year. In cirrhosis, HCC surveillance should continue after HCV cure, although it is uncertain if this should be indefinite. For patients with advanced fibrosis (F3), guidelines are inconsistent in their recommendations. We evaluated the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis. APPROACH AND RESULTS: This systematic review and meta-analysis identified 44 studies (107,548 person-years of follow-up) assessing the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis. The incidence of HCC was 2.1 per 100 person-years (95% CI, 1.9-2.4) among patients with cirrhosis and 0.5 per 100 person-years (95% CI, 0.3-0.7) among patients with F3 fibrosis. In a meta-regression analysis among patients with cirrhosis, older age (adjusted rate ratio [aRR] per 10-year increase in mean/median age, 1.32; 95% CI, 1.00-1.73) and prior decompensation (aRR per 10% increase in the proportion of patients with prior decompensation, 1.06; 95% CI, 1.01-1.12) were associated with an increased incidence of HCC. Longer follow-up after HCV cure was associated with a decreased incidence of HCC (aRR per year increase in mean/median follow-up, 0.87; 95% CI, 0.79-0.96). CONCLUSIONS: Among patients with cirrhosis, the incidence of HCC decreases over time after HCV cure and is lowest in patients with younger age and compensated cirrhosis. The substantially lower incidence in F3 fibrosis is below the recommended threshold for cost-effective screening. The results should encourage the development of validated predictive models that better identify at-risk individuals, especially among patients with F3 fibrosis.
引用
- Lockart I, Yeo MGH, Hajarizadeh B, et al. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology. 2022. PMID: 35030279. doi:10.1002/hep.32341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。